These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25788127)

  • 1. Rational drug design applied to myeloperoxidase inhibition.
    Van Antwerpen P; Zouaoui Boudjeltia K
    Free Radic Res; 2015 Jun; 49(6):711-20. PubMed ID: 25788127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping myeloperoxidase to identify its promiscuity properties using docking and molecular dynamics simulations.
    Ramírez-Durán LA; Rosales-Hernández MC; Hernández-Rodríguez M; Mendieta-Wejebe JE; Trujillo-Ferrara J; Correa-Basurto J
    Curr Pharm Des; 2013; 19(12):2204-15. PubMed ID: 23016839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
    Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
    Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of chemical features of potent myeloperoxidase inhibitors.
    Soubhye J; Meyer F; Furtmüller P; Obinger C; Dufrasne F; Antwerpen PV
    Future Med Chem; 2016 Jul; 8(11):1163-77. PubMed ID: 27402298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.
    Aldib I; Soubhye J; Zouaoui Boudjeltia K; Vanhaeverbeek M; Rousseau A; Furtmüller PG; Obinger C; Dufrasne F; Nève J; Van Antwerpen P; Prévost M
    J Med Chem; 2012 Aug; 55(16):7208-18. PubMed ID: 22793255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloperoxidase: a target for new drug development?
    Malle E; Furtmüller PG; Sattler W; Obinger C
    Br J Pharmacol; 2007 Nov; 152(6):838-54. PubMed ID: 17592500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of myeloperoxidase inhibitors.
    Galijasevic S
    Bioorg Med Chem Lett; 2019 Jan; 29(1):1-7. PubMed ID: 30466896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification.
    Van Antwerpen P; Prévost M; Zouaoui-Boudjeltia K; Babar S; Legssyer I; Moreau P; Moguilevsky N; Vanhaeverbeek M; Ducobu J; Nève J; Dufrasne F
    Bioorg Med Chem; 2008 Feb; 16(4):1702-20. PubMed ID: 18063373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
    Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK
    Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloperoxidase Inhibitors as Potential Drugs.
    Lazarević-Pasti T; Leskovac A; Vasić V
    Curr Drug Metab; 2015; 16(3):168-90. PubMed ID: 26279325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease.
    Premkumar J; Sampath P; Sanjay R; Chandrakala A; Rajagopal D
    ChemMedChem; 2020 Jul; 15(13):1187-1199. PubMed ID: 32368837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
    Hu CH; Neissel Valente MW; Halpern OS; Jusuf S; Khan JA; Locke GA; Duke GJ; Liu X; Duclos FJ; Wexler RR; Kick EK; Smallheer JM
    Bioorg Med Chem Lett; 2021 Jun; 42():128010. PubMed ID: 33811992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the mechanism by which tryptophan analogs inhibit human myeloperoxidase.
    Sliskovic I; Abdulhamid I; Sharma M; Abu-Soud HM
    Free Radic Biol Med; 2009 Oct; 47(7):1005-13. PubMed ID: 19596067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry--activity-based protein profiling.
    Ward J; Spath SN; Pabst B; Carpino PA; Ruggeri RB; Xing G; Speers AE; Cravatt BF; Ahn K
    Biochemistry; 2013 Dec; 52(51):9187-201. PubMed ID: 24320749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites.
    Shiba Y; Kinoshita T; Chuman H; Taketani Y; Takeda E; Kato Y; Naito M; Kawabata K; Ishisaka A; Terao J; Kawai Y
    Chem Res Toxicol; 2008 Aug; 21(8):1600-9. PubMed ID: 18620432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae).
    Bensalem S; Soubhye J; Aldib I; Bournine L; Nguyen AT; Vanhaeverbeek M; Rousseau A; Boudjeltia KZ; Sarakbi A; Kauffmann JM; Nève J; Prévost M; Stévigny C; Maiza-Benabdesselam F; Bedjou F; Van Antwerpen P; Duez P
    J Ethnopharmacol; 2014 Jun; 154(2):361-9. PubMed ID: 24746482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors.
    Soubhye J; Aldib I; Delporte C; Prévost M; Dufrasne F; Antwerpen PV
    Curr Med Chem; 2016; 23(35):3975-4008. PubMed ID: 27281130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).
    Patnaik A; Axford L; Deng L; Cohick E; Ren X; Loi S; Kecman S; Hollis-Symynkywicz M; Harrison TJ; Papillon JPN; Dales N; Hamann LG; Lee L; Regard JB; Marcinkeviciene J; Marro ML; Patterson AW
    Bioorg Med Chem; 2020 Jun; 28(12):115548. PubMed ID: 32503688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.
    Soubhye J; Chikh Alard I; Aldib I; Prévost M; Gelbcke M; De Carvalho A; Furtmüller PG; Obinger C; Flemmig J; Tadrent S; Meyer F; Rousseau A; Nève J; Mathieu V; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
    J Med Chem; 2017 Aug; 60(15):6563-6586. PubMed ID: 28671460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ordered cleavage of myeloperoxidase ester bonds releases active site heme leading to inactivation of myeloperoxidase by benzoic acid hydrazide analogs.
    Huang J; Smith F; Panizzi P
    Arch Biochem Biophys; 2014 Apr; 548():74-85. PubMed ID: 24632143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.